Telix Exceeds Fy24 Guidance With Us142m Q4 Revenue
Telix Pharmaceuticals Limited ASX: TLX, Nasdaq: TLX, Telix, the Company today provides an update on its commercial and operational performance for the quarter ended 31 December 2024 Q4 2024.
Sustained revenue growth
- Q4 2024 unaudited revenue of approximately US142 million AU218 million 1 , represents an increase of 46 over the prior year corresponding quarter Q4 2023: US97 million or AU148 million and a quarter-over-quarter increase of 5 Q3 2024: US135 million or AU201 million.
- Telixs revenue is currently generated predominantly from sales of Illuccix , its diagnostic radiopharmaceutical for prostate cancer PET 2 imaging.
Full year guidance exceeded
- Total FY2024 unaudited revenue is approximately US517 million AU783 million exceeding previously stated guidance of US490 million to US510 million AU745 million to AU776 million, representing a 55 increase over FY2023.
- FY2024 investment into research and development R D remains in line with guidance, funded by earnings generated from product sales.
- The Company intends to provide FY2025 guidance when it reports audited FY2024 annual results on 20 February 2025 .
Q4 2024 business update
Dr. Christian Behrenbruch , Managing Director and Group Chief Executive Officer, Telix, said, This has been another great quarter of commercial performance. Strong sales of Illuccix have led Telix to close out the year with revenue above guidance, while significantly progressing our strategic priorities. Boosting our balance sheet and the Nasdaq listing were major corporate milestones. The acquisition of FAP-targeting assets is a major addition to our superb product pipeline. We are well-positioned for significant expansion, including planned launches of multiple imaging products in key markets and advancing late-stage therapeutic assets into pivotal trials. 2025 is shaping up to be transformative year for Telix.